Anavex Life Sciences’ (AVXL) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a report published on Monday,Benzinga reports. D. Boral Capital currently has a $46.00 price objective on the biotechnology company’s stock.

Separately, HC Wainwright lifted their price objective on shares of Anavex Life Sciences from $40.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, December 26th.

Anavex Life Sciences Stock Performance

Shares of AVXL stock opened at $11.33 on Monday. The company has a market capitalization of $960.97 million, a P/E ratio of -22.66 and a beta of 0.70. The company’s 50 day moving average price is $9.61 and its two-hundred day moving average price is $7.10. Anavex Life Sciences has a 52 week low of $3.25 and a 52 week high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last announced its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03. Analysts forecast that Anavex Life Sciences will post -0.55 earnings per share for the current year.

Hedge Funds Weigh In On Anavex Life Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in AVXL. Orion Capital Management LLC increased its holdings in shares of Anavex Life Sciences by 666.7% during the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock worth $65,000 after acquiring an additional 10,000 shares during the last quarter. PVG Asset Management Corp bought a new stake in Anavex Life Sciences in the 3rd quarter valued at $74,000. Atria Investments Inc bought a new stake in Anavex Life Sciences in the 3rd quarter valued at $76,000. BNP Paribas Financial Markets lifted its position in Anavex Life Sciences by 97.0% during the third quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 7,421 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Anavex Life Sciences by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 6,366 shares in the last quarter. 31.55% of the stock is owned by institutional investors.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.